Abstracts tagged "scleroderma and systemic sclerosis"

Abstract Number: 1877 • 2016 ACR/ARHP Annual Meeting
Confirmatory Factor Analysis and Assessment of Differential Item Functioning of the Satisfaction with Appearance Scale in Systemic Sclerosis: A Comparison Across Sex, Race/Ethnicity and Disease Subtype
Lisa Jewett¹, Linda Kwakkenbos², Vanessa L. Malcarne³, Marie-Eve Carrier² and Brett D. Thombs⁴, ¹Department of Psychiatry, McGill University, Montreal, QC, Canada, ²McGill University, Montreal, QC, Canada, ³SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: The Satisfaction with Appearance Scale (SWAP) has been used to assess dissatisfaction with appearance and social discomfort relative to disfigurement in systemic sclerosis (scleroderma,…
Abstract Number: 832 • 2015 ACR/ARHP Annual Meeting
The Validity and Reliability of Online Obituaries As a Source of Mortality Data
Medha Soowamber¹, John T. Granton², Fatemeh Bavaghar-Zaeimi³ and Sindhu R. Johnson^4,5, ¹Rheumatology, University of Toronto/ Toronto Western Hospital, Toronto, ON, Canada, ²Medicine, Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Rheumatology, Toronto Scleroderma Program, Toronto Western Hospital and Mount Sinai Hospital, Toronto, ON, Canada, ⁴Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵Institute of Health Policy, Management and Evaluation,, University of Toronto, Toronto, ON, Canada
Background/Purpose: Loss to follow-up is a major threat to the conduct of chronic disease cohort research. Tracking the survival status of patients who are lost…
Abstract Number: 2986 • 2015 ACR/ARHP Annual Meeting
Systemic Sclerosis Patients on Intensive Care Unit – Reasons for Admission and Determinants of Outcome
Svetlana I. Nihtyanova¹, Francesco Figorilli², Christopher P. Denton³, Banwari Agarwal² and Voon H. Ong¹, ¹Rheumatology, UCL Division of Medicine, London, United Kingdom, ²ITU, Royal Free Hospital, London, United Kingdom, ³Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Little has been published on systemic sclerosis (SSc) patients requiring admission to Intensive Care Unit (ICU) for organ support; published results suggest respiratory failure…
Abstract Number: 841 • 2015 ACR/ARHP Annual Meeting
Prevalence of Systemic Sclerosis in Primary Biliary Cirrhosis Using the New ACR/EULAR Classification Criteria
Boyang Zheng¹, Catherine Vincent², Marvin J. Fritzler³, Jean-Luc Senécal⁴, Martial Koenig⁵ and France Joyal⁵, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ²Division of Hepatology, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴Department of Medicine, Division of Rheumatology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁵Department of Medicine, Division of Internal Medicine, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) is a well established disease associated with primary biliary cirrhosis (PBC), however original 1980 American College of Rheumatology (ACR) criteria have…
Abstract Number: 2995 • 2015 ACR/ARHP Annual Meeting
Genome Wide Analysis in Scleroderma Renal Crisis: Defining Genetic Risk in Patients with RNA Polymerase III Auto-Antibodies
Maria C Fonseca¹, Sandra Guerra¹, Edward Stern^1,2, Svetlana I. Nihtyanova¹, David Abraham³, Aine Burns², Mark Harber² and Christopher P. Denton⁴, ¹Rheumatology, UCL Division of Medicine, London, United Kingdom, ²Nephrology, Royal Free Hospital, London, United Kingdom, ³Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC) is a severe complication of systemic sclerosis (SSc). Most SSc cases demonstrate a disease-specific antinuclear antibody including anti-RNA polymerase III…
Abstract Number: 845 • 2015 ACR/ARHP Annual Meeting
Modelling of Longitudinal Changes in Lung Function in Patients with Systemic Sclerosis and Their Association with Development of Pulmonary Hypertension
Svetlana I. Nihtyanova¹, Voon H. Ong¹ and Christopher P. Denton², ¹Rheumatology, UCL Division of Medicine, London, United Kingdom, ²Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: The majority of published models for prediction of PH use cross-sectional data, while studies exploring the use of repeated measurements of lung function tests…
Abstract Number: 3006 • 2015 ACR/ARHP Annual Meeting
Cell-Free Circulating DNA in Systemic Sclerosis: Increased Levels and Global Cytosine Hypomethylation
Shadia Nada¹, Omar Oraibi², Farouk Abu Alhana², Nawaf Almeshal², Yongqing Wang², Nezam Altorok³ and Bashar Kahaleh⁴, ¹Internal Medicine, Divison of Rheumatology, The University of Toledo, Toledo, OH, ²The University of Toledo, Toledo, OH, ³Internal Medicine, Division of Rheumatology, The University of Toledo, Toledo, OH, ⁴Medicine/Rheumatology, The University of Toledo, Toledo, OH
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by endothelial dysfunction, vascular injury, and activation of fibroblasts leading to organ fibrosis. The precise etiology…
Abstract Number: 849 • 2015 ACR/ARHP Annual Meeting
A Computational Tool for Individualized Prognosis of Percent of Predicted Forced Vital Capacity Trajectories in Systemic Sclerosis
Peter Schulam¹, Colin Ligon², Robert Wise³, Laura K. Hummers⁴, Fredrick M. Wigley⁵ and Suchi Saria^1,6, ¹Department of Computer Science, Johns Hopkins University, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Departments of Biostatistics, and Health Policy and Management, Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Interstitial lung disease (ILD) is a common cause of mortality in systemic sclerosis (Ssc). Decreased forced vital capacity (FVC) in Ssc-ILD is associated with…
Abstract Number: 3007 • 2015 ACR/ARHP Annual Meeting
Cold Receptor Expression and Function in Human Dermal Fibroblast: Possible Role in the Pathogenesis of Scleroderma Fibrosis
Yongqing Wang¹, John Sun¹, Shadia Nada², Nezam Altorok³ and Bashar Kahaleh⁴, ¹The University of Toledo, Toledo, OH, ²Internal Medicine, Divison of Rheumatology, The University of Toledo, Toledo, OH, ³Internal Medicine, Division of Rheumatology, The University of Toledo, Toledo, OH, ⁴Medicine/Rheumatology, The University of Toledo, Toledo, OH
Background/Purpose: Enhanced cold sensitivity is an early and consistent phenomenon in scleroderma (SSc). We previously demonstrated increased expression of the transient receptor potential melastatine 8…
Abstract Number: 1079 • 2015 ACR/ARHP Annual Meeting
The Potential Effect on Recruitment of Restricting Skin Scores Eligibility Criteria in Early Diffuse Scleroderma Trials
Robyn T. Domsic¹, Dinesh Khanna², Mary Lucas³, Virginia D. Steen⁴, Daniel E. Furst⁵, Robert Lafyatis⁶ and Thomas A. Medsger Jr.⁷, ¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Medicine, University of Pittsburgh Scleroderma Center, Pittsburgh, PA, ⁴Rheumatology, Georgetown University Medical Center, Washington, DC, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Boston University School of Medicine, Boston, MA, ⁷Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: There is increasing interest in cohort enrichment for clinical trials of early diffuse SSc (dcSSc). Recent EUSTAR database analysis (Maurer et al. 2015)…
Abstract Number: 1175 • 2015 ACR/ARHP Annual Meeting
Blood Outgrowth Endothelial Cells Isolated from Systemic Sclerosis Patients Exhibit a Pro-Inflammatory Phenotype
Robert Good¹, Sarah L. Trinder², Christopher P. Denton³, David Abraham⁴ and Alan M. Holmes¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Centre for Rheumatology and Connective Tissue Diseases, UCL, London, United Kingdom, ³Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁴Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom
Background/Purpose: Vascular complications are a key pathological feature of systemic sclerosis (SSc) affecting the microcirculation and arterioles. Under normal circumstances the endothelium acts as a…
Abstract Number: 1872 • 2015 ACR/ARHP Annual Meeting
Symptomatic and Electrodiagnostic Features of Peripheral Neuropathy in Scleroderma
Julie J. Paik¹, Andrew Mammen², Fredrick M. Wigley³, Ami A. Shah⁴, Laura K. Hummers⁵ and Michael Polydefkis⁶, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Neurology, Johns Hopkins University, Baltimore, MD
Title: Symptomatic and electrodiagnostic features of peripheral neuropathy in scleroderma Background/Purpose: Peripheral neuropathy in scleroderma has been poorly characterized and the prevalence is unknown. The…
Abstract Number: 1882 • 2015 ACR/ARHP Annual Meeting
The Predictive Value of Pulmonary Function Tests to Diagnose Interstitial Lung Disease in Adults with Early Diffuse Cutaneous Systemic Sclerosis
Elana J. Bernstein¹, Veronica J. Berrocal², Virginia D. Steen³, Victoria K. Shanmugam^4,5, Ami A. Shah⁶, Monique E. Hinchcliff⁷, Faye N. Hant⁸, Jessica K. Gordon⁹, Tracy M. Frech¹⁰, Robyn T. Domsic¹¹, Shervin Assassi¹² and Dinesh Khanna¹³, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³Rheumatology, Georgetown University Medical Center, Washington, DC, ⁴Division of Rheumatology, The George Washington University, Washington, DC, ⁵Director, Division of Rheumatology, The George Washington University, Washington, DC, ⁶Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Rheumatology, Northwestern University, Chicago, IL, ⁸Dept of Medicine, Medical University of South Carolina, Charleston, SC, ⁹Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁰Div of Rheumatology, University of Utah, Salt Lake City, UT, ¹¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹²Rheumatology, University of Texas Medical School at Houston, Houston, TX, ¹³Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Patients with diffuse cutaneous systemic sclerosis (dcSSc) have…
Abstract Number: 1888 • 2015 ACR/ARHP Annual Meeting
There Is a Need for New Systemic Sclerosis Subset Criteria: A Content Analytic Approach
Sindhu Johnson¹, Medha Soowamber², Jaap Fransen³, Dinesh Khanna⁴, Frank H.J. van den Hoogen⁵, Murray Baron⁶, Marco Matucci Cerinic⁷, Christopher P. Denton⁸, Thomas A. Medsger Jr.⁹, Patricia E. Carreira¹⁰, Gabriela Riemekasten¹¹, Jorg HW. Distler¹², Armando Gabrielli¹³, Virginia D. Steen¹⁴, Lorinda Chung¹⁵, Richard Silver¹⁶, John Varga¹⁷, Ulf Müller-Ladner¹⁸, Madelon C. Vonk¹⁹, Ulrich A. Walker²⁰, Frank Wollheim²¹, Ariane L. Herrick²², Daniel E. Furst²³, Lazlo Czirjak²⁴, Otylia Kowal-Bielecka²⁵, Francesco Del Galdo²⁶, Maurizio Cutolo²⁷, Nicolas Hunzelmann²⁸, Charles Murray²⁹, Ivan Foeldvari³⁰, Luc Mouthon³¹, Nemanja Damjanov³², Bashar Kahaleh³³, Tracy M. Frech³⁴, Shervin Assassi³⁵, Lesley Ann Saketkoo³⁶ and Janet E. Pope³⁷, ¹Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ²Rheumatology, University of Toronto/ Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ⁴Medicine, University of Michigan, Ann Arbor, MI, ⁵Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁶Pavillion A, Rm 216, Jewish General Hospital, Montreal, QC, Canada, ⁷Department of BioMedicine, Division of Rheumatology, Transition Unit, University of Florence, Firenze, Italy, ⁸Centre for Rheumatology, Royal Free Hospital, London, United Kingdom, ⁹Medicine/Rheumatology, Univ of Pittsburgh, Pittsburgh, PA, ¹⁰Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Rheumatology, Human medicine, BERLIN, Germany, ¹²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ¹³Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, ¹⁴Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁵Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ¹⁶Div Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ¹⁷Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁸Rheumatology, Internal Medicine, Bad Nauheim, Germany, ¹⁹Rheumatology, Rheumatology, Nijmegen, Netherlands, ²⁰Rheumatology, Systemic Sclerosis, Basel, Switzerland, ²¹Rheumatology, Lund University Hospital, Lund, Sweden, ²²Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²⁴University of Pécs Medical Center, Pécs, Hungary, ²⁵Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ²⁶University of Leeds, Leeds, United Kingdom, ²⁷Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ²⁸Department of Dermatology, University of Cologne, Cologne, Germany, ²⁹Department of Gastroenterology, Royal Free Hospital, London, United Kingdom, ³⁰Rheumatology, Hamburg, Germany, ³¹Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, ³²Resavska 69, Institute of Rheumatology, Belgrade, Serbia, ³³Medicine/Rheumatology, The University of Toledo, Toledo, OH, ³⁴Div of Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT, ³⁵Rheumatology, University of Texas Medical School at Houston, Houston, TX, ³⁶Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ³⁷University of Western Ontario, London, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is a family of diseases unified by the presence of immune activation, vasculopathy and fibrosis. The concept of SSc subsets cannot…
Abstract Number: 1889 • 2015 ACR/ARHP Annual Meeting
Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease
Natalie K. Kozij¹, John T. Granton², Philip E. Silkoff³, John Thenganatt⁴, Shobha Chakravorty⁴ and Sindhu R. Johnson⁵, ¹Department of Medicine, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada., Toronto, ON, Canada, ²Medicine, Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Temple University, Philadelphia, PA, ⁴Respirology, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ⁵Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: We evaluated the ability of alveolar and conducting airway nitric oxide (NO) to discriminate between systemic sclerosis (SSc) with and without lung involvement, idiopathic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].